A number of sessions on the second day of IPWatchdog LIVE examined the state of U.S. IP policy and the potential for change ...
California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
Gov. Gavin Newsom has yet to make good on his promise of state-produced, affordable insulin for diabetics. What's the hold up ...
As biopharma players continue to parse out what the second Trump Administration means for the industry, Pfizer CEO Albert ...
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...
(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in ...
One of the worst flu seasons in years has reached its peak and is improving, officials with the Centers for Disease Control ...
Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
Eli Lilly is making a massive $50 billion investment in U.S. manufacturing. This move more than doubles their previous $23 ...
Eli Lilly and Company, Hims & Hers Health, UnitedHealth Group, Walmart, Tempus AI, Johnson & Johnson, and Merck & Co., Inc. are the seven Medical stocks to watch today, according to MarketBeat’s stock ...
At the four new sites, Lilly expects to create more than 3,000 jobs for engineers, scientists, operations personnel, and lab ...
The news comes amid the possibility that President Trump imposes a 25% tariff on pharmaceuticals, which could encourage manufacturers to begin reshoring their services.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback